Market research

Artificial Intelligence in Remote Patient Monitoring Market

Explore licensesfrom $3,939

Assess the study’s coverageRead the public overview, then compare the chapter outline with your research brief.

19report chapters

Public research overviewHow we research Research team

Artificial Intelligence Is Reshaping Remote Patient Monitoring

Artificial intelligence (AI) is expanding the role of remote patient monitoring (RPM) from data collection toward continuous risk identification, clinical prioritization, and personalized intervention. AI-enabled systems can analyze streams from connected devices, patient-reported outcomes, and electronic health records to help care teams recognize deterioration earlier and manage chronic conditions beyond traditional clinical settings. Adoption depends on reliable connectivity, clinically appropriate validation, workflow integration, cybersecurity, privacy protection, and reimbursement alignment.

360iResearch introduction

Inside the research

Coverage at a glance

Selected branches from the published table of contents. Follow a chapter to see every subchapter in context.

  1. Chapter 7 Component

    • Hardware
    • Services
    • Software
    View chapter
  2. Chapter 8 Technology

    • Computer Vision
    • Deep Learning
    • Machine Learning
    • Natural Language Processing
    View chapter
  3. Chapter 9 Device Type

    • Contactless Devices
    • Wearable Devices
    View chapter

From Device Connectivity to Integrated, Outcome-Oriented Care

The RPM landscape is shifting from standalone devices toward interoperable platforms that combine physiological signals, symptom data, clinical context, and patient engagement tools. This transformation places greater emphasis on reducing false alerts, supporting clinician workload management, and embedding actionable insights into established care pathways. Regulatory scrutiny is also increasing around software as a medical device, algorithmic transparency, data governance, and evidence of clinical benefit. Organizations that treat AI as a workflow capability rather than an isolated technology are better positioned to translate monitoring data into timely care decisions.

AI’s Cumulative Impact: Earlier Signals, Better Prioritization, Higher Governance Demands

AI can identify patterns across high-frequency monitoring data that may be difficult to detect through manual review, enabling risk stratification, anomaly detection, adherence support, and more targeted follow-up. Its cumulative impact is strongest when models are continuously evaluated against clinically meaningful outcomes and used with appropriate human oversight. At the same time, biased training data, model drift, explainability limitations, automation bias, and uneven digital access can create safety and equity risks. Responsible deployment therefore requires representative datasets, prospective validation, monitoring of performance by patient group, clear escalation rules, and defined accountability for clinical decisions.

Regional Insights: Adoption Reflects Infrastructure, Regulation, and Care-Delivery Models

North America is characterized by mature digital-health infrastructure, extensive provider networks, and active attention to reimbursement, privacy, and medical-device regulation. Europe emphasizes cross-border data governance, interoperability, patient rights, and evidence-based integration within public and mixed health systems. Asia-Pacific combines advanced connected-health capabilities in several economies with substantial variation in rural access, digital infrastructure, and regulatory maturity. Latin America is focusing on extending specialist access and chronic-care management while addressing connectivity, affordability, and fragmented delivery systems. The Middle East is investing in digitally enabled healthcare transformation, with implementation shaped by national strategies, data localization, and workforce readiness. Africa presents significant opportunity for mobile-enabled and decentralized monitoring, but deployment must account for connectivity constraints, device affordability, local clinical capacity, and data stewardship.

Group Insights: Standards and Cooperation Shape Scalable Deployment

ASEAN members face varied levels of digital infrastructure and regulatory development, making interoperable architectures and shared implementation practices especially important. BRICS economies span large and diverse populations, creating strong needs for cost-conscious solutions, locally representative data, and adaptable care models. The European Union is shaped by coordinated privacy, AI, medical-device, and health-data requirements, alongside demand for interoperable systems. G7 health systems generally have stronger research capacity and digital infrastructure but must address aging populations, workforce pressure, procurement complexity, and equitable access. GCC countries are advancing centralized digital-health programs and can benefit from common governance, multilingual design, and cross-border interoperability. NATO members have an additional interest in resilient health information infrastructure, continuity of care, cybersecurity, and secure data exchange during system disruption.

Country Insights: National Context Determines Clinical and Technical Priorities

Australia is prioritizing digitally supported care across dispersed populations, making connectivity, integration, and remote clinical oversight important considerations. Brazil and Mexico must balance large geographic coverage with uneven access, affordability, and health-system fragmentation. Canada and the United States are focused on interoperability, chronic-care pathways, reimbursement, privacy, and evidence for safe clinical adoption. China, India, and Russia require approaches that can operate across substantial regional differences in infrastructure, language, workforce, and regulatory implementation. Japan, South Korea, and Singapore-oriented models within the wider Asia-Pacific context emphasize aging, advanced connectivity, and integration with technologically sophisticated care systems. France, Germany, Italy, Spain, and the United Kingdom are navigating public-system integration, data governance, procurement, and evidence requirements, with national differences in reimbursement and implementation. Across all countries, local validation, cybersecurity, patient consent, and clinician training remain essential.

Priorities for Leaders: Build Trustworthy AI Into Existing Care Pathways

Industry leaders should begin with high-value use cases such as deterioration detection, medication or adherence support, and workload prioritization, then validate them prospectively in representative patient populations. Establish multidisciplinary governance spanning clinical safety, data protection, cybersecurity, ethics, procurement, and patient advocacy. Select platforms with open interoperability standards, auditable data flows, human-review controls, and tools for monitoring model performance after deployment. Define escalation protocols, service-level responsibilities, and fallback procedures before expanding beyond pilot settings. Finally, measure outcomes that matter to patients and providers-including avoidable utilization, response time, adherence, equity, clinician workload, and patient experience-rather than relying solely on technical accuracy.

Research Methodology: Evidence-Based Assessment of AI-Enabled Monitoring

This executive summary applies a structured qualitative assessment of artificial intelligence in remote patient monitoring. The analysis considers peer-reviewed research, clinical and regulatory publications, health-system implementation evidence, interoperability standards, privacy and cybersecurity guidance, and publicly documented policy developments. Findings are organized by technology shifts, AI capabilities, region, economic and security group, and country. Interpretation emphasizes clinical utility, implementation readiness, governance, access, and operational constraints. Because national policies and AI systems evolve rapidly, conclusions should be reviewed against current regulatory requirements, local clinical evidence, and post-deployment performance data before investment or implementation decisions are made.

Conclusion: Scale AI Through Evidence, Interoperability, and Responsible Governance

AI is making RPM more capable of converting continuous patient information into prioritized, clinically relevant action. The strongest opportunities lie in earlier recognition of risk, more personalized support, and better use of limited clinical capacity, but these benefits are not automatic. Sustainable progress requires validated models, interoperable infrastructure, equitable access, transparent governance, and meaningful human oversight. Leaders that align technology deployment with patient outcomes, clinician workflows, and jurisdiction-specific requirements can advance RPM while managing the safety, privacy, and trust challenges that accompany intelligent automation.

Research report

Table of contents

  1. 1.Preface
    1. 1.1Objectives of the Study
    2. 1.2Market Definition
    3. 1.3Market Segmentation & Coverage
    4. 1.4Years Considered for the Study
    5. 1.5Currency Considered for the Study
    6. 1.6Language Considered for the Study
    7. 1.7Key Stakeholders
  2. 2.Research Methodology
    1. 2.1Introduction
    2. 2.2Research Design
      1. 2.2.1Primary Research
      2. 2.2.2Secondary Research
    3. 2.3Research Framework
      1. 2.3.1Qualitative Analysis
      2. 2.3.2Quantitative Analysis
    4. 2.4Market Size Estimation
      1. 2.4.1Top-Down Approach
      2. 2.4.2Bottom-Up Approach
    5. 2.5Data Triangulation
    6. 2.6Research Outcomes
    7. 2.7Research Assumptions
    8. 2.8Research Limitations
  3. 3.Executive Summary
    1. 3.1Introduction
    2. 3.2CXO Perspective
    3. 3.3New Revenue Opportunities
    4. 3.4Next-Generation Business Models
    5. 3.5Industry Roadmap
  4. 4.Market Overview
    1. 4.1Introduction
    2. 4.2Industry Ecosystem & Value Chain Analysis
      1. 4.2.1Supply-Side Analysis
      2. 4.2.2Demand-Side Analysis
      3. 4.2.3Stakeholder Analysis
    3. 4.3Market Dynamics
      1. 4.3.1Key Drivers
      2. 4.3.2Key Restraints
      3. 4.3.3Key Opportunities
      4. 4.3.4Key Challenges
    4. 4.4Porter’s Five Forces Analysis
    5. 4.5PESTLE Analysis
    6. 4.6Market Outlook
      1. 4.6.1Near-Term Market Outlook (0–2 Years)
      2. 4.6.2Medium-Term Market Outlook (3–5 Years)
      3. 4.6.3Long-Term Market Outlook (5–10 Years)
    7. 4.7Go-to-Market Strategy
  5. 5.Market Insights
    1. 5.1Consumer Insights & End-User Perspective
    2. 5.2Consumer Experience Benchmarking
    3. 5.3Opportunity Mapping
    4. 5.4Distribution Channel Analysis
    5. 5.5Pricing Trend Analysis
    6. 5.6Regulatory Compliance & Standards Framework
    7. 5.7ESG & Sustainability Analysis
    8. 5.8Disruption & Risk Scenarios
    9. 5.9Return on Investment & Cost-Benefit Analysis
  6. 6.Cumulative Impact of Artificial Intelligence 2026
  7. 7.Artificial Intelligence in Remote Patient Monitoring Market, by Component
    1. 7.1Introduction
    2. 7.2Hardware
      1. 7.2.1Connectivity Devices
      2. 7.2.2Monitoring Devices
    3. 7.3Services
      1. 7.3.1Managed Services
        1. 7.3.1.1Remote Monitoring
        2. 7.3.1.2Support Services
      2. 7.3.2Professional Services
        1. 7.3.2.1Consulting
        2. 7.3.2.2Integration
        3. 7.3.2.3Training
    4. 7.4Software
      1. 7.4.1Analytics Software
      2. 7.4.2Platform Software
  8. 8.Artificial Intelligence in Remote Patient Monitoring Market, by Technology
    1. 8.1Introduction
    2. 8.2Computer Vision
      1. 8.2.1Image Recognition
      2. 8.2.2Video Analytics
    3. 8.3Deep Learning
      1. 8.3.1Convolutional Neural Networks
      2. 8.3.2Recurrent Neural Networks
    4. 8.4Machine Learning
      1. 8.4.1Reinforcement Learning
      2. 8.4.2Supervised Learning
      3. 8.4.3Unsupervised Learning
    5. 8.5Natural Language Processing
      1. 8.5.1Speech Recognition
      2. 8.5.2Text Analytics
  9. 9.Artificial Intelligence in Remote Patient Monitoring Market, by Device Type
    1. 9.1Introduction
    2. 9.2Contactless Devices
      1. 9.2.1Camera Based Sensors
      2. 9.2.2Environmental Sensors
      3. 9.2.3Radar Sensors
    3. 9.3Wearable Devices
      1. 9.3.1Patches
      2. 9.3.2Smart Garments
      3. 9.3.3Wristbands
  10. 10.Artificial Intelligence in Remote Patient Monitoring Market, by Mode Of Delivery
    1. 10.1Introduction
    2. 10.2Cloud
    3. 10.3On Premise
  11. 11.Artificial Intelligence in Remote Patient Monitoring Market, by Service Type
    1. 11.1Introduction
    2. 11.2Managed Services
    3. 11.3Professional Services
  12. 12.Artificial Intelligence in Remote Patient Monitoring Market, by Application
    1. 12.1Introduction
    2. 12.2Chronic Disease Management
      1. 12.2.1Cardiac Monitoring
      2. 12.2.2Diabetes Management
      3. 12.2.3Respiratory Monitoring
    3. 12.3Elderly Care
      1. 12.3.1Fall Detection
      2. 12.3.2Medication Management
    4. 12.4Emergency Alert
      1. 12.4.1Automated Alert
      2. 12.4.2Panic Button
    5. 12.5Fitness Monitoring
      1. 12.5.1Activity Tracking
      2. 12.5.2Nutrition Monitoring
  13. 13.Artificial Intelligence in Remote Patient Monitoring Market, by End User
    1. 13.1Introduction
    2. 13.2Ambulatory Care Settings
    3. 13.3Clinics
    4. 13.4Home Care Settings
    5. 13.5Hospitals
  14. 14.Artificial Intelligence in Remote Patient Monitoring Market, by Region
    1. 14.1Introduction
    2. 14.2Asia-Pacific
    3. 14.3North America
    4. 14.4Latin America
    5. 14.5Europe
    6. 14.6Middle East
    7. 14.7Africa
  15. 15.Artificial Intelligence in Remote Patient Monitoring Market, by Group
    1. 15.1Introduction
    2. 15.2ASEAN
    3. 15.3GCC
    4. 15.4European Union
    5. 15.5BRICS
    6. 15.6G7
    7. 15.7NATO
  16. 16.Artificial Intelligence in Remote Patient Monitoring Market, by Country
    1. 16.1Introduction
    2. 16.2United States
    3. 16.3Canada
    4. 16.4Mexico
    5. 16.5Brazil
    6. 16.6United Kingdom
    7. 16.7Germany
    8. 16.8France
    9. 16.9Russia
    10. 16.10Italy
    11. 16.11Spain
    12. 16.12China
    13. 16.13India
    14. 16.14Japan
    15. 16.15Australia
    16. 16.16South Korea
  17. 17.Competitive Landscape
    1. 17.1Market Share Analysis, 2025
    2. 17.2Market Concentration Analysis, 2025
      1. 17.2.1Concentration Ratio (CR)
      2. 17.2.2Herfindahl Hirschman Index (HHI)
    3. 17.3Recent Developments & Impact Analysis, 2025
    4. 17.4Product Portfolio Analysis, 2025
    5. 17.5Benchmarking Analysis, 2025
  18. 18.Company Profiles
    1. 18.1Accuhealth Global Inc
    2. 18.2AiCure, LLC
    3. 18.3Apexon
    4. 18.4Binah.ai Ltd
    5. 18.5Biofourmis Inc.
    6. 18.6Cardiomo Care, Inc.
    7. 18.7ChroniSense Medical, Ltd.
    8. 18.8CU-BX Automotive Technologies Ltd.
    9. 18.9Current Health Limited
    10. 18.10DrKumo Inc.
    11. 18.11Ejenta, Inc.
    12. 18.12Feebris Ltd.
    13. 18.13Gyant.com, Inc.
    14. 18.14Huma Therapeutics Limited
    15. 18.15iBeat, Inc.
    16. 18.16iHealth Labs, Inc.
    17. 18.17Implicity
    18. 18.18Jorie Healthcare Patners LLC
    19. 18.19Myia Labs Inc.
    20. 18.20Neteera Technologies Ltd.
    21. 18.21Philips Healthcare
    22. 18.22Resideo Technologies, Inc
    23. 18.23Senseonics Holdings, Inc
    24. 18.24Somatix Inc.
    25. 18.25Zephyr AI
  19. 19.Key Experts

Loading the sample request form…